
How can the KISQALI dose be adjusted to help manage adverse reactions?
For patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), the once-daily KISQALI® (ribociclib) dose can be reduced from 600 mg (3 x 200-mg tablets) orally to 400 mg (2 x 200-mg tablets) to one 200-mg tablet, as needed, to help manage adverse reactions. Review the clinical guidance below for KISQALI dose adjustments in mBC.1
DOSE REDUCTIONS
For patients with HR+/HER2- mBC,
Dose reductions with KISQALI mean no need for new mid-cycle prescriptions or additional costs
KISQALI is given as 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) with either AI or fulvestrant1:
AI should be taken once daily (continuously); in men and premenopausal women, an LHRH agonist should be administered according to current clinical practice guidelines; or
Fulvestrant 500 mg should be administered intramuscularly on Days 1, 15, and 29, and once monthly thereafter; in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines
Dose adjustments for adverse reactions should be made in a stepwise order by reducing the number of tablets taken to 2 x 200-mg tablets or 1 x 200-mg tablet.1
If dose reduction below 200 mg/day is required, discontinue treatment1
KISQALI dose modification is recommended based on individual safety and tolerability1
KISQALI can be taken with or without food1
AI, aromatase inhibitor; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone; mBC, metastatic breast cancer.
PEER PERSPECTIVE
Nick McAndrew, MD, discusses KISQALI dose adjustments and patient adherence in HR+/HER2- mBC
How do KISQALI single-strength tablets allow for simple dose reductions? Dr McAndrew shares his perspective and personal insights from his experience with KISQALI dose adjustments in HR+/HER2- mBC.
Dr McAndrew has been compensated for his time by Novartis Pharmaceuticals Corporation.

